AnaptysBio, Inc (ANAB) company profile
Close on Oct 19, 2026Market cap $2.28BP/E –Yield –
About AnaptysBio
Pharmaceutical Preparations, SIC 2834
AnaptysBio, Inc. is a clinical-stage biotechnology company that focuses on the research, development, and commercialization of antibody product candidates. The company develops therapeutic antibodies targeting various diseases across its research, development, and collaborative program segments. Its pipeline and partnered assets include rosnilimab, imsidolimab, ANB032, ANB033, ANB101, and dostarlimab, an anti-PD-1 therapy marketed under the name Jemperli. The company partners with and licenses its therapeutic assets to global biopharmaceutical corporations, including GlaxoSmithKline, Vanda Pharmaceuticals, and Centessa Pharmaceuticals.
The company conducts clinical trials and research operations in the United States and internationally, including Australia, in coordination with regulatory bodies such as the U.S. Food and Drug Administration and foreign health authorities. AnaptysBio is incorporated in Delaware and maintains its principal executive offices and operational facilities in San Diego, California.
Summary of the business section of AnaptysBio's latest annual report, written by StockData.
Company profile
Company
- Legal name
- AnaptysBio, Inc
- Headquarters
- San Diego, CA
- Address
- 10770 Wateridge Circle, Suite 210 92121
- Phone
- (858) 362-6295
- Website
- anaptysbio.com
- Employees
- 104, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- June 30
- Auditor
- KPMG LLP, San Diego, California
Stock & identifiers
- Ticker
- ANAB
- Exchange
- Nasdaq
- IPO date
- Jan 26, 2017
- Shares outstanding
- 30M, Sep 16, 2026
- Public float
- $632.72M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 15-for-10, Apr 20, 2026
- SEC CIK
- 1370053
- CUSIP
- 032724106
- ISIN
- US0327241065
- FIGI
- BBG0026ZDHR0
- Share class FIGI
- BBG0026ZDHT8
- LEI
- 529900HH4WQT03IG1A12
- EIN
- 20-3828755
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Daniel Faga | President, CEO, Director | 510,564 |
| Paul F. Lizzul | Chief Medical Officer | 42,088 |
| Christopher M. Murphy | Chief Financial Officer | – |
| Eric J. Loumeau | CHIEF LEGAL OFFICER | 12,835 |
| Dennis Mulroy | CHIEF FINANCIAL OFFICER | 21,852 |
| Hollings Renton | Director | 10,995 |
| John A. Orwin | Director | 17,995 |
| John P. Schmid | Director | 37,652 |
| Owen Hughes | Director | – |
| Susannah Gray | Director | – |
| Magda Marquet | Director | 20,930 |
| J. Anthony Ware | Director | 9,630 |
| Rita Jain | Director | 11,864 |
| Dennis M. Fenton | Director | 4,965 |
| EcoR1 Capital, LLC | Director | 7,880,094 |
| Oleg Nodelman | Director | 7,520,424 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $6.13M | $41.74M | $2.19M | $156 | – |
| FY2024 | $13.63M | $9.16M | $3.91M | $43 | – |
| FY2023 | $7.46M | -$1.74M | $2.35M | $69 | – |
| FY2022 Daniel Faga | $24.44M | $28.51M | $3.83M | $89 | – |
| FY2022 Hamza Suria | $7.25M | $3.71M | $3.83M | $89 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Daniel Faga President and Chief Executive Officer and Director | $706.01K | $1.59M | $3.35M | $465.97K | $24.31K | $6.13M | -55% |
| Paul Lizzul Chief Medical Officer | $545.75K | $505.70K | $1.06M | $221.03K | $28.41K | $2.37M | -48% |
| Dennis Mulroy Chief Financial Officer | $510.07K | $397.44K | $836.69K | $224.43K | $39.30K | $2.01M | -38% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jan 26, 2017
- Offer price
- $15.00
- Securities offered
- 5,000,000
- Gross proceeds
- $75.00M
- Exchange
- Nasdaq
- First trading day
- Jan 26, 2017
- First-day close
- $17.00+13.3%
- Lock-up ends (est.)
- Jul 25, 2017
“The initial public offering price of our common stock is $15.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of January 31, 2026, we had 104 employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 20, 2026 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Dec 1, 2021 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jan 26, 2017 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 17, 2017 | Listing | Registration of securities on an exchange (Form 8-A) |
| Nov 20, 2007 | Name change | Name changed from ANAPTYS BIOSCIENCES INC to ANAPTYSBIO INC |
See a number that looks wrong?